Black Diamond Therapeutics’ (BDTX) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Black Diamond Therapeutics (NASDAQ:BDTX) in a research report released on Friday,RTT News reports. They currently have a $11.00 price objective on the stock, down from their prior price objective of $16.00. Wedbush also issued estimates for Black Diamond Therapeutics’ Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.23) EPS and Q4 2026 earnings at ($0.24) EPS.

Black Diamond Therapeutics Stock Down 1.1 %

NASDAQ:BDTX opened at $1.88 on Friday. Black Diamond Therapeutics has a twelve month low of $1.77 and a twelve month high of $7.66. The company has a market cap of $106.38 million, a P/E ratio of -1.41 and a beta of 2.52. The business has a 50 day moving average price of $2.23 and a two-hundred day moving average price of $3.16.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. As a group, analysts anticipate that Black Diamond Therapeutics will post -1.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Black Diamond Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. D. E. Shaw & Co. Inc. purchased a new position in shares of Black Diamond Therapeutics in the fourth quarter worth about $37,000. Intech Investment Management LLC raised its stake in shares of Black Diamond Therapeutics by 49.1% in the 4th quarter. Intech Investment Management LLC now owns 19,247 shares of the company’s stock valued at $41,000 after acquiring an additional 6,340 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Black Diamond Therapeutics by 429.6% in the 4th quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company’s stock valued at $41,000 after acquiring an additional 15,355 shares during the period. SG Americas Securities LLC acquired a new position in shares of Black Diamond Therapeutics in the fourth quarter valued at approximately $42,000. Finally, Wells Fargo & Company MN grew its holdings in shares of Black Diamond Therapeutics by 41.8% in the fourth quarter. Wells Fargo & Company MN now owns 20,119 shares of the company’s stock valued at $43,000 after purchasing an additional 5,932 shares in the last quarter. 95.47% of the stock is currently owned by hedge funds and other institutional investors.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.